{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:38:29Z","timestamp":1764182309361,"version":"3.46.0"},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R56AI165448"],"award-info":[{"award-number":["R56AI165448"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P01AI162242"],"award-info":[{"award-number":["P01AI162242"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["5UM1AI068618"],"award-info":[{"award-number":["5UM1AI068618"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>With a goal of unveiling mechanisms by which vaccines can provide protection against HIV-1 acquisition, several studies have explored correlates of risk of HIV-1 acquisition in HVTN 505, which was a phase IIb trial conducted to assess the safety and efficacy of a DNA plasmid and recombinant adenovirus serotype 5-vectored HIV vaccine regimen among individuals in the United States who were vulnerable to acquiring HIV. While this trial failed to meet its predetermined efficacy criteria, both immunological and virological correlates of reduced risk of acquisition have been reported, suggesting that at least some vaccine recipients were protected from some viruses. In this work, we describe application of a novel Positive-Unlabeled machine learning-based approach to infer protection status among vaccine recipients that did not acquire HIV, resulting in improved power to detect potential correlates of immunity. Having established the analytical robustness of protection status predictions using cross-validation and permutation testing strategies, we report increased confidence in previously identified correlates of risk, such as vaccine-elicited anti\u2013HIV-1 Env glycoprotein IgG3 antibodies and antibody-dependent phagocytosis, and the new observation of an inverse correlation between inferred vaccine-mediated protection and virus-specific IgA responses. Though its biological validity is not established, this inference approach offers a new means to use case-control datasets to identify candidate markers of effective immune responses in the context of low vaccine efficacy.<\/jats:p>","DOI":"10.1371\/journal.pcbi.1013705","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:33:21Z","timestamp":1764182001000},"page":"e1013705","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Candidate correlates of protection in the HVTN505 HIV-1 vaccine efficacy trial identified by positive-unlabeled learning"],"prefix":"10.1371","volume":"21","author":[{"given":"Shiwei","family":"Xu","sequence":"first","affiliation":[]},{"given":"Aaron","family":"Hudson","sequence":"additional","affiliation":[]},{"given":"Holly E.","family":"Janes","sequence":"additional","affiliation":[]},{"given":"Georgia D.","family":"Tomaras","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4253-3476","authenticated-orcid":true,"given":"Margaret E.","family":"Ackerman","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"pcbi.1013705.ref001","doi-asserted-by":"crossref","first-page":"590780","DOI":"10.3389\/fimmu.2020.590780","article-title":"Major Scientific Hurdles in HIV Vaccine Development: Historical Perspective and Future Directions","volume":"11","author":"T Ng\u2019uni","year":"2020","journal-title":"Front Immunol"},{"issue":"23","key":"pcbi.1013705.ref002","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"S Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"issue":"22","key":"pcbi.1013705.ref003","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1310566","article-title":"Efficacy trial of a DNA\/rAd5 HIV-1 preventive vaccine","volume":"369","author":"SM Hammer","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"pcbi.1013705.ref004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185959","article-title":"Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120","volume":"12","author":"AC deCamp","year":"2017","journal-title":"PLoS One"},{"issue":"9","key":"pcbi.1013705.ref005","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/infdis\/jix086","article-title":"Higher T-Cell Responses Induced by DNA\/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial","volume":"215","author":"HE Janes","year":"2017","journal-title":"J Infect Dis"},{"issue":"8","key":"pcbi.1013705.ref006","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/infdis\/jiy008","article-title":"Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial","volume":"217","author":"Y Fong","year":"2018","journal-title":"J Infect Dis"},{"issue":"11","key":"pcbi.1013705.ref007","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1172\/JCI126391","article-title":"Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk","volume":"129","author":"SD Neidich","year":"2019","journal-title":"J Clin Invest"},{"issue":"11","key":"pcbi.1013705.ref008","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","article-title":"Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition","volume":"384","author":"L Corey","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"pcbi.1013705.ref009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1011469","article-title":"Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials","volume":"19","author":"NN Mkhize","year":"2023","journal-title":"PLoS Pathog"},{"key":"pcbi.1013705.ref010","doi-asserted-by":"crossref","first-page":"104590","DOI":"10.1016\/j.ebiom.2023.104590","article-title":"Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition","volume":"93","author":"KE Seaton","year":"2023","journal-title":"EBioMedicine"},{"issue":"9","key":"pcbi.1013705.ref011","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/s41591-022-01953-6","article-title":"Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition","volume":"28","author":"PB Gilbert","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"pcbi.1013705.ref012","doi-asserted-by":"crossref","first-page":"8299","DOI":"10.1038\/s41467-023-43384-y","article-title":"High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials","volume":"14","author":"DB Reeves","year":"2023","journal-title":"Nat Commun"},{"issue":"2","key":"pcbi.1013705.ref013","doi-asserted-by":"crossref","first-page":"33","DOI":"10.37737\/ace.22005","article-title":"Introduction to Matching in Case-Control and Cohort Studies","volume":"4","author":"M Iwagami","year":"2022","journal-title":"Ann Clin Epidemiol"},{"issue":"3","key":"pcbi.1013705.ref014","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2307\/2529548","article-title":"Efficiency of case-control studies with multiple controls per case: continuous or dichotomous data","volume":"31","author":"HK Ury","year":"1975","journal-title":"Biometrics"},{"issue":"1","key":"pcbi.1013705.ref015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/sim.4780050106","article-title":"Choosing the number of controls in a matched case-control study, some sample size, power and efficiency considerations","volume":"5","author":"JM Taylor","year":"1986","journal-title":"Stat Med"},{"issue":"1","key":"pcbi.1013705.ref016","doi-asserted-by":"crossref","first-page":"2204020","DOI":"10.1080\/21645515.2023.2204020","article-title":"Foundations for improved vaccine correlate of risk analysis using positive-unlabeled learning","volume":"19","author":"NS Kelkar","year":"2023","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"pcbi.1013705.ref017","article-title":"Positive-unlabeled learning to infer protection status and identify correlates in vaccine efficacy field trials","volume":"27","author":"S Xu","year":"2024","journal-title":"iScience"},{"issue":"1","key":"pcbi.1013705.ref018","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s12859-024-05834-2","article-title":"Leveraging permutation testing to assess confidence in positive-unlabeled learning applied to high-dimensional biological datasets","volume":"25","author":"S Xu","year":"2024","journal-title":"BMC Bioinformatics"},{"key":"pcbi.1013705.ref019","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.patrec.2013.06.010","article-title":"A bagging SVM to learn from positive and unlabeled examples","volume":"37","author":"F Mordelet","year":"2014","journal-title":"Pattern Recognit Lett"},{"key":"pcbi.1013705.ref020","article-title":"Partially supervised classification of text documents.","volume-title":"ICML","author":"B Liu","year":"2002"},{"issue":"1","key":"pcbi.1013705.ref021","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1023\/A:1010933404324","article-title":"Random Forests","volume":"45","author":"L Breiman","year":"2001","journal-title":"Mach Learn"},{"issue":"14","key":"pcbi.1013705.ref022","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"BF Haynes","year":"2012","journal-title":"N Engl J Med"},{"issue":"22","key":"pcbi.1013705.ref023","doi-asserted-by":"crossref","first-page":"9019","DOI":"10.1073\/pnas.1301456110","article-title":"Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG","volume":"110","author":"GD Tomaras","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"pcbi.1013705.ref024","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2031499","article-title":"Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults","volume":"384","author":"GE Gray","year":"2021","journal-title":"N Engl J Med"},{"key":"pcbi.1013705.ref025","unstructured":"Johnson J. Johnson & Johnson and global partners announce results from phase 2b Imbokodo HIV vaccine clinical trial in young women in sub-Saharan Africa. 2021."},{"key":"pcbi.1013705.ref026","unstructured":"Johnson J. Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial. 2023."},{"issue":"9653","key":"pcbi.1013705.ref027","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"SP Buchbinder","year":"2008","journal-title":"Lancet"},{"issue":"6439","key":"pcbi.1013705.ref028","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1126\/science.aav5095","article-title":"Structural topology defines protective CD8+ T cell epitopes in the HIV proteome","volume":"364","author":"GD Gaiha","year":"2019","journal-title":"Science"},{"issue":"6623","key":"pcbi.1013705.ref029","doi-asserted-by":"crossref","DOI":"10.1126\/science.add6502","article-title":"Vaccination induces HIV broadly neutralizing antibody precursors in humans","volume":"378","author":"DJ Leggat","year":"2022","journal-title":"Science"},{"issue":"6541","key":"pcbi.1013705.ref030","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe9233","article-title":"Modulation of MHC-E transport by viral decoy ligands is required for RhCMV\/SIV vaccine efficacy","volume":"372","author":"MC Verweij","year":"2021","journal-title":"Science"},{"issue":"16","key":"pcbi.1013705.ref031","doi-asserted-by":"crossref","first-page":"8334","DOI":"10.1128\/JVI.00908-15","article-title":"Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection","volume":"89","author":"KO Saunders","year":"2015","journal-title":"J Virol"},{"issue":"10","key":"pcbi.1013705.ref032","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1038\/s41591-018-0161-0","article-title":"Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV","volume":"24","author":"ME Ackerman","year":"2018","journal-title":"Nat Med"},{"issue":"9","key":"pcbi.1013705.ref033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003618","article-title":"A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies","volume":"9","author":"RW Sanders","year":"2013","journal-title":"PLoS Pathog"},{"issue":"228","key":"pcbi.1013705.ref034","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007736","article-title":"Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines","volume":"6","author":"AW Chung","year":"2014","journal-title":"Sci Transl Med"},{"issue":"4","key":"pcbi.1013705.ref035","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.cell.2015.10.027","article-title":"Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology","volume":"163","author":"AW Chung","year":"2015","journal-title":"Cell"},{"issue":"228","key":"pcbi.1013705.ref036","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007730","article-title":"Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination","volume":"6","author":"NL Yates","year":"2014","journal-title":"Sci Transl Med"},{"issue":"22","key":"pcbi.1013705.ref037","doi-asserted-by":"crossref","first-page":"9019","DOI":"10.1073\/pnas.1301456110","article-title":"Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG","volume":"110","author":"GD Tomaras","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"pcbi.1013705.ref038","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140925","article-title":"IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees","volume":"5","author":"S Fischinger","year":"2020","journal-title":"JCI Insight"},{"issue":"1","key":"pcbi.1013705.ref039","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.08.033","article-title":"Passive Transfer of Vaccine-Elicited Antibodies Protects against SIV in Rhesus Macaques","volume":"183","author":"G Alter","year":"2020","journal-title":"Cell"},{"issue":"6245","key":"pcbi.1013705.ref040","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1126\/science.aab3886","article-title":"Protective efficacy of adenovirus\/protein vaccines against SIV challenges in rhesus monkeys","volume":"349","author":"DH Barouch","year":"2015","journal-title":"Science"},{"issue":"10143","key":"pcbi.1013705.ref041","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(18)31364-3","article-title":"Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)","volume":"392","author":"DH Barouch","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"pcbi.1013705.ref042","article-title":"Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodies","volume":"16","author":"TH Chu","year":"2020","journal-title":"PLoS Pathog"},{"issue":"10","key":"pcbi.1013705.ref043","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/0161-5890(89)90114-4","article-title":"The functional properties of Fc gamma RI, II and III on myeloid cells: a comparative study of killing of erythrocytes and tumor cells mediated through the different Fc receptors","volume":"26","author":"L Shen","year":"1989","journal-title":"Mol Immunol"},{"key":"pcbi.1013705.ref044","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.69577","article-title":"Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1","volume":"10","author":"S Shangguan","year":"2021","journal-title":"Elife"},{"key":"pcbi.1013705.ref045","unstructured":"Kenny A, et al. Immune correlates analysis of the Imbokodo HIV-1 vaccine efficacy trial. In: AIDS 2022. Montreal (CA); 2022."},{"issue":"2","key":"pcbi.1013705.ref046","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/infdis\/jiac260","article-title":"Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk","volume":"226","author":"Z Moodie","year":"2022","journal-title":"J Infect Dis"},{"key":"pcbi.1013705.ref047","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jim.2010.12.016","article-title":"A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples","volume":"366","author":"ME Ackerman","year":"2011","journal-title":"J Immunol Methods"},{"issue":"24","key":"pcbi.1013705.ref048","doi-asserted-by":"crossref","first-page":"12449","DOI":"10.1128\/JVI.01708-08","article-title":"Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia","volume":"82","author":"GD Tomaras","year":"2008","journal-title":"J Virol"},{"key":"pcbi.1013705.ref049","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jim.2018.01.013","article-title":"Optimization and qualification of an Fc Array assay for assessments of antibodies against HIV-1\/SIV","volume":"455","author":"EP Brown","year":"2018","journal-title":"J Immunol Methods"},{"key":"pcbi.1013705.ref050","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jim.2017.01.010","article-title":"Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles","volume":"443","author":"EP Brown","year":"2017","journal-title":"J Immunol Methods"},{"key":"pcbi.1013705.ref051","first-page":"2825","article-title":"Scikit-learn: Machine Learning in Python","volume":"12","author":"F Pedregosa","year":"2011","journal-title":"J Mach Learn Res"},{"issue":"3","key":"pcbi.1013705.ref052","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41592-019-0686-2","article-title":"SciPy 1.0: fundamental algorithms for scientific computing in Python","volume":"17","author":"P Virtanen","year":"2020","journal-title":"Nat Methods"}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1013705","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:33:30Z","timestamp":1764182010000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1013705"}},"subtitle":[],"editor":[{"given":"Jessica M.","family":"Conway","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":52,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1013705","relation":{},"ISSN":["1553-7358"],"issn-type":[{"type":"electronic","value":"1553-7358"}],"subject":[],"published":{"date-parts":[[2025,11,26]]}}}